<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <title>Detail Page</title>
    <link rel="stylesheet" href="../details.css">

    <meta name="citation_title" content="Reactivation of Mutant p53 in NSCLC: Cytotoxic Potential of PRIMA-1(Met) and Etoposide Combination">
    <meta name="citation_author" content="NFatma T. KAHRAMAN">
    <meta name="citation_author" content="Nilüfer İMİR">

    <meta name="citation_publication_date" content="21.03.2025">
    <meta name="citation_journal_title" content="Journal of Balkan Science and Technology (JBST)">
    <meta name="citation_volume" content="4">
    <meta name="citation_issue" content="1">

    <meta name="citation_firstpage" content="17">
    <meta name="citation_lastpage" content="22">
    <meta name="citation_pdf_url" content="https://jbst-nku.github.io/articles/2025_4_1_3.pdf">


</head>
<body>

<div class="det-page-container">
    <div class="detail-container">
        <div class="det-article-type">Research Article</div>
        <div class="det-title">Combination Therapy in p53-Mutant NSCLC</div>
        <div class="volume-issn-container">
            <div class="det-year"> 2025</div>
            <div class="det-volume"> 4</div>
            <div class="det-issue"> 1</div>
            <div class="det-page"> 17-22</div>
            <div class="det-date"> 21.05.2025
            </div>

            <div class="det-eissn"> 2822-4566</div>
        </div>

        <div class="author-container">
            <div class="det-author">Fatma T. KAHRAMAN</div>
            <div class="det-author">Nilüfer İMİR</div>
        </div>

        <div class="doi-pdf-container">
            <div class="det-doi"><a href="https://www.doi.org/10.55848/jbst.2025.08
">10.55848/jbst.2025.08
            </a></div>
            <a class="det-pdf" href="../articles/2025_4_1_3.pdf"><img class="pdf" src="../images/pdf.png"></a>
        </div>
        <div class="det-abstract">Lung cancer, particularly non-small cell lung cancer (NSCLC), remains a leading cause of cancer-related mortality. Mutations in the tumor suppressor protein p53 contribute to tumor progression and chemoresistance, making p53 reactivation a promising therapeutic strategy. PRIMA-1(Met), a small molecule designed to restore mutant p53 function, has shown potential in various cancers. This study investigates the cytotoxic effects of PRIMA-1(Met), alone and in combination with etoposide, on NSCLC cell lines. Human NSCLC cell lines A549 (p53-wild type) and NCI-H1975 (p53-mutant) were treated with PRIMA-1(Met) and/or etoposide. Cell viability was assessed using the WST-1 assay at 24, 48, and 72 hours. Statistical analyses were performed using one-way ANOVA followed by Tukey’s test. PRIMA-1(Met) exhibited a dose- and time-dependent cytotoxic effect, with NCI-H1975 cells showing greater sensitivity compared to A549 cells (p<0.001). Etoposide treatment alone induced cytotoxicity, but its combination with PRIMA-1(Met) significantly enhanced cell death in both cell lines, particularly in p53-mutant NCI-H1975 cells (p<0.001). These findings suggest that PRIMA-1(Met) is more effective in p53-mutant NSCLC cells and that its combination with etoposide enhances its therapeutic potential. This study supports further investigation into PRIMA-1(Met) as a targeted therapy for p53-mutant NSCLC, particularly in combination with standard chemotherapy.</div>
        <div class="det-keywords det-datex-header">PRIMA-1(Met),
            p53,
            NSCLC,
            Etoposide,
            Cytotoxicity,
            Combination Therapy</div>
        <div class="det-correspondence">Nilüfer İMİR<a class="def-correspondence-email" href="mailto: ngimir@akdeniz.edu.tr
 "> ngimir@akdeniz.edu.tr</a></div>
        <div class="det-received-date det-datex-header">14.03.2025</div>
        <div class="det-accepted-date det-datex-header">024.04.2025</div>
        <div class="det-published-date det-datex-header">16.05.2025</div>
        <div class="det-cite det-datex-header"> Fatma T. KAHRAMAN, Nilüfer İMİR  JBST. August 2024.39-42 http://doi.org/10.55848/jbst.2025.08</div>
        <div class="det-license" style="font-size: 1.5vw"> This work is licensed under a Creative Commons Attribution-Non Comercial 4.0 International License.</div>
        <a rel="license" href="http://creativecommons.org/licenses/by-nc/4.0/"><img alt="Creative Commons License" style="border-width:0" src="https://i.creativecommons.org/l/by-nc/4.0/88x31.png" /></a><a rel="license" href="http://creativecommons.org/licenses/by-nc/4.0/"></a>

        <div><a href="https://jbst-nku.github.io/">Return to JSBT Archive</a></div>
        <div><a href="http://jbst.nku.edu.tr/">Return to JSBT Main Page</a></div>
    </div>
</div>
</body>
</html>